Cargando…
Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients
Tigecycline has in vitro activity against multidrug-resistant and extensively drug-resistant Acinetobacter baumannii (MDR/XDRAB), and may constitute an alternative therapy for treating pneumonia caused by MDR/XDRAB. The aim of this study was to compare the efficacy of tigecycline-based therapy with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775052/ https://www.ncbi.nlm.nih.gov/pubmed/26934182 http://dx.doi.org/10.1371/journal.pone.0150642 |
_version_ | 1782419016323694592 |
---|---|
author | Kim, Won-Young Moon, Jae-Young Huh, Jin Won Choi, Sang-Ho Lim, Chae-Man Koh, Younsuck Chong, Yong Pil Hong, Sang-Bum |
author_facet | Kim, Won-Young Moon, Jae-Young Huh, Jin Won Choi, Sang-Ho Lim, Chae-Man Koh, Younsuck Chong, Yong Pil Hong, Sang-Bum |
author_sort | Kim, Won-Young |
collection | PubMed |
description | Tigecycline has in vitro activity against multidrug-resistant and extensively drug-resistant Acinetobacter baumannii (MDR/XDRAB), and may constitute an alternative therapy for treating pneumonia caused by MDR/XDRAB. The aim of this study was to compare the efficacy of tigecycline-based therapy with colistin-based therapy in patients with MDR/XDRAB pneumonia. Between January 2009 and December 2010, patients in the intensive care unit who were diagnosed with MDR/XDRAB pneumonia and treated with either tigecycline or colistin mono-/combination therapy were reviewed. A total of 70 patients were included in our analysis. Among them, 30 patients received tigecycline-based therapy, and 40 patients received colistin-based therapy. Baseline characteristics were similar in the two groups. Clinical success rate was 47% in the tigecycline group and 48% in the colistin group (P = 0.95). There were no differences between the groups with regard to other clinical outcomes, with the exception that nephrotoxicity was observed only in the colistin group (0% vs. 20%; P = 0.009). Clinical and microbiological success rates were numerically higher, and mortality rates were numerically lower in combination therapy group than in the monotherapy group. Multivariate analysis indicated that monotherapy was independently associated with increased clinical failure (aOR, 3.96; 95% CI, 1.03–15.26; P = 0.046). Our results suggest that tigecycline-based therapy was tolerable and the clinical outcome was comparable to that of colistin-based therapy for patients with MDR/XDRAB pneumonia. In addition, combination therapy may be more useful than monotherapy in treatment of MDR/XDRAB pneumonia. |
format | Online Article Text |
id | pubmed-4775052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-47750522016-03-10 Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients Kim, Won-Young Moon, Jae-Young Huh, Jin Won Choi, Sang-Ho Lim, Chae-Man Koh, Younsuck Chong, Yong Pil Hong, Sang-Bum PLoS One Research Article Tigecycline has in vitro activity against multidrug-resistant and extensively drug-resistant Acinetobacter baumannii (MDR/XDRAB), and may constitute an alternative therapy for treating pneumonia caused by MDR/XDRAB. The aim of this study was to compare the efficacy of tigecycline-based therapy with colistin-based therapy in patients with MDR/XDRAB pneumonia. Between January 2009 and December 2010, patients in the intensive care unit who were diagnosed with MDR/XDRAB pneumonia and treated with either tigecycline or colistin mono-/combination therapy were reviewed. A total of 70 patients were included in our analysis. Among them, 30 patients received tigecycline-based therapy, and 40 patients received colistin-based therapy. Baseline characteristics were similar in the two groups. Clinical success rate was 47% in the tigecycline group and 48% in the colistin group (P = 0.95). There were no differences between the groups with regard to other clinical outcomes, with the exception that nephrotoxicity was observed only in the colistin group (0% vs. 20%; P = 0.009). Clinical and microbiological success rates were numerically higher, and mortality rates were numerically lower in combination therapy group than in the monotherapy group. Multivariate analysis indicated that monotherapy was independently associated with increased clinical failure (aOR, 3.96; 95% CI, 1.03–15.26; P = 0.046). Our results suggest that tigecycline-based therapy was tolerable and the clinical outcome was comparable to that of colistin-based therapy for patients with MDR/XDRAB pneumonia. In addition, combination therapy may be more useful than monotherapy in treatment of MDR/XDRAB pneumonia. Public Library of Science 2016-03-02 /pmc/articles/PMC4775052/ /pubmed/26934182 http://dx.doi.org/10.1371/journal.pone.0150642 Text en © 2016 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kim, Won-Young Moon, Jae-Young Huh, Jin Won Choi, Sang-Ho Lim, Chae-Man Koh, Younsuck Chong, Yong Pil Hong, Sang-Bum Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients |
title | Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients |
title_full | Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients |
title_fullStr | Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients |
title_full_unstemmed | Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients |
title_short | Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients |
title_sort | comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant acinetobacter baumannii pneumonia in critically ill patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775052/ https://www.ncbi.nlm.nih.gov/pubmed/26934182 http://dx.doi.org/10.1371/journal.pone.0150642 |
work_keys_str_mv | AT kimwonyoung comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT moonjaeyoung comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT huhjinwon comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT choisangho comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT limchaeman comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT kohyounsuck comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT chongyongpil comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients AT hongsangbum comparableefficacyoftigecyclineversuscolistintherapyformultidrugresistantandextensivelydrugresistantacinetobacterbaumanniipneumoniaincriticallyillpatients |